Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in their interests in the company's Ordinary shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding director share allocations and does not contain financial performance data.
Material Changes
The material change reported is the provisional allocation of awards to Non-Executive Directors on December 31, 2008, resulting from the annual reinvestment of dividends paid throughout 2008. These allocations were communicated to the Company and the Directors on January 5, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Annual dividend reinvestment awards for Non-Executive Directors.
- Allocation Date: December 31, 2008 (notified January 5, 2009).
- Share Classes: Awards were made in both Ordinary shares and American Depository Shares (ADSs).
- Valuation: Average prices for Ordinary shares were approximately £12.58, while ADSs were priced at approximately $36.51.
- Participants: Includes directors such as Sir Christopher Gent, Sir Ian Prosser, and Dr. Stephanie Burns, among others.